Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

The cannabinoid CB2 agonist AM1710 differentially suppresses distinct pathological pain states and attenuates morphine tolerance and withdrawal

Ai-Ling Li, Xiaoyan Lin, Amey S Dhopeshwarkar, Ana Carla Thomaz, Lawrence M Carey, Yingpeng Liu, Spyros P Nikas, Alexandros Makriyannis, Ken Mackie and Andrea G Hohmann
Molecular Pharmacology December 3, 2018, mol.118.113233; DOI: https://doi.org/10.1124/mol.118.113233
Ai-Ling Li
1 Indiana University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoyan Lin
1 Indiana University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amey S Dhopeshwarkar
1 Indiana University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Carla Thomaz
1 Indiana University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence M Carey
1 Indiana University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yingpeng Liu
2 Northeastern University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Spyros P Nikas
2 Northeastern University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandros Makriyannis
2 Northeastern University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken Mackie
1 Indiana University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea G Hohmann
1 Indiana University;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

AM1710, a cannabilactone CB2 agonist, suppresses chemotherapy-induced neuropathic pain in rodents without producing tolerance or unwanted side effects associated with CB1 receptors. However, the signaling profile of AM1710 remains incompletely characterized. It is not known whether AM1710 behaves as a broad spectrum analgesic and/or suppresses the development of opioid tolerance and physical dependence. In vitro, AM1710 inhibited forskolin-stimulated cAMP production and produced enduring activation of ERK1/2 phosphorylation in HEK cells stably expressing mCB2. However, species differences in the signaling profile of AM1710 were observed between HEK cells stably expressing mCB2 and hCB2. In vivo, AM1710 produced a sustained inhibition of chemotherapy-induced allodynia induced by paclitaxel. Prior history of AM1710 treatment (5 mg/kg/day x 12 day, i.p.) delayed the development of analgesic tolerance to morphine and attenuated morphine-induced physical dependence in paclitaxel-treated mice. However, AM1710 (10 mg/kg, i.p.) did not precipitate CB1-receptor mediated withdrawal in mice rendered tolerant to Δ9-tetrahydrocannabinol, suggesting AM1710 does not behave as a functional CB1 antagonist in vivo. Furthermore, AM1710 (1, 3, 10 mg/kg, i.p.) did not suppress established mechanical allodynia induced by complete Freund's adjuvant (CFA) or by partial sciatic nerve ligation (PSNL). Similarly, prophylactic and chronic dosing with AM1710 (10 mg/kg, i.p.) did not produce anti-allodynic efficacy in the CFA model. By contrast, gabapentin suppressed allodynia in both CFA and PSNL models. Our results indicate that AM1710 is not a broad spectrum analgesic agent in mice and suggest the need to identify signaling pathways underlying CB2 therapeutic efficacy to identify appropriate indications for clinical translation.

  • Cannabinoid receptors
  • Drug tolerance/dependence
  • Pain
  • The American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Molecular Pharmacology: 103 (2)
Molecular Pharmacology
Vol. 103, Issue 2
1 Feb 2023
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The cannabinoid CB2 agonist AM1710 differentially suppresses distinct pathological pain states and attenuates morphine tolerance and withdrawal
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

The cannabinoid CB2 agonist AM1710 differentially suppresses distinct pathological pain states and attenuates morphine tolerance and withdrawal

Ai-Ling Li, Xiaoyan Lin, Amey S Dhopeshwarkar, Ana Carla Thomaz, Lawrence M Carey, Yingpeng Liu, Spyros P Nikas, Alexandros Makriyannis, Ken Mackie and Andrea G Hohmann
Molecular Pharmacology December 3, 2018, mol.118.113233; DOI: https://doi.org/10.1124/mol.118.113233

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

The cannabinoid CB2 agonist AM1710 differentially suppresses distinct pathological pain states and attenuates morphine tolerance and withdrawal

Ai-Ling Li, Xiaoyan Lin, Amey S Dhopeshwarkar, Ana Carla Thomaz, Lawrence M Carey, Yingpeng Liu, Spyros P Nikas, Alexandros Makriyannis, Ken Mackie and Andrea G Hohmann
Molecular Pharmacology December 3, 2018, mol.118.113233; DOI: https://doi.org/10.1124/mol.118.113233
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
  • Benzbromarone relaxes airway smooth muscle via BK activation
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics